Rho GTPase-Activating Protein 35 rs1052667 Polymorphism and Osteosarcoma Risk and Prognosis
Figure 2
Survival analysis of ARHGAP35 rs1052667 polymorphism in strata of treatment status. According to whether cases received radical treatment (RT) including both surgical resection and adjuvant chemotherapy, 247 osteosarcoma cases were divided into two groups: RT (+) and RT (−). ((a), (c)) Overall survival and ARHGAP35 rs1052667 polymorphism in strata of RT status. ((b), (d)) Tumor recurrence-free survival and ARHGAP35 rs1052667 polymorphism in strata of status. Cumulative hazard function was plotted by Kaplan-Meier’s methodology, and value was calculated with two-sided log-rank tests. MST, the median overall survival time; MRT, the median tumor recurrence-free survival time.
